先天性纤维素素缺乏症:不是那么罕见
Alexander Couzens1, Marguerite Neerman-Arbez1
1Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva and Institute of Genetics and Genomics in Geneva (iGE3), Geneva, Switzerland.
Hamostaseologie
|March 12, 2025
概括
先天性纤维素素缺乏症 (CFDs) 比以前认为的更常见,并且在遗传上更复杂. 更新的估计表明,衰退型差价合约每百万人中影响29人,占主导地位的差价合约每百万人中影响高达15,000人.
科学领域:
- 遗传学 是一个遗传学.
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 先天性纤维素素缺乏症 (CFDs) 传统上被视为罕见的单一性疾病.
- 新出现的证据表明,CFD更为普遍和遗传复杂,涉及FGB,FGA和FGG以外的多个基因.
- 患者的症状,如出血和血栓形成,可能源于多基因影响.
研究的目的:
- 审查最近在理解CFD遗传基础方面的进展.
- 通过使用新型遗传数据集,提供对CFD的最新全球流行估计.
- 探索导致CFD表型的遗传变异性.
主要方法:
- 关于CFD遗传学的最新进展的文献综述.
- 对 gnomAD v4.1.0.0 的分析 数据库 (超过80万个人).
- 基于FGB,FGA和FGG基因中预测的有害变异频率的CFD流行率估计.
主要成果:
- 衰减继承的CFD (同卵性基因型) 估计在每百万分之29左右.
- 主要遗传的CFD (异合体基因型) 估计高达每百万约15,000.
- 增加的患病率估计与gnomAD v4.1.0.0中的扩展和更多样化的遗传数据有关.
结论:
- 差价合约比以前认为的更为普遍.
- 遗传复杂性和更广泛的变异谱系有助于CFD流行.
- 更新的流行数据对于对差价合约的临床理解和管理至关重要.
相关概念视频
Inborn Errors of Metabolism
121
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
121
Disorders of Hemostasis
674
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
674
Anticoagulant Drugs: Low-Molecular-Weight Heparins
586
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
586
Clot Retraction and Fibrinolysis
3.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.1K
Extrinsic and Intrinsic Pathways of Hemostasis
4.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.5K
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K


